What is a normal non-fasting triglyceride level? Why the line is 175, not 150

In 2016 the European Atherosclerosis Society and the European Federation of Clinical Chemistry and Laboratory Medicine published a joint consensus statement, led by Børge Nordestgaard, on how laboratories should handle lipid tests taken without fasting. It recommended non-fasting samples as the routine, and it told laboratories where to flag a result: for non-fasting samples, "triglycerides ≥2 mmol/L (175 mg/dL)"; for fasting samples, "triglycerides ≥1.7 mmol/L (150 mg/dL)." A non-fasting triglyceride under 175 mg/dL is therefore not flagged as abnormal.

Two details change how to read that table. First, these are not the usual laboratory reference limits. The authors note that laboratories normally flag a result outside the age- and sex-specific reference interval, the 2.5th to 97.5th percentiles; this consensus flags at "desirable concentration cut-points" instead, which is why the flags catch so many people. By the authors' estimate, 27 percent of adults in a typical Western or Northern European country would have a non-fasting triglyceride of 175 or above. Second, the consensus says non-fasting and fasting measurements "should be complementary but not mutually exclusive": a non-fasting test is the default, not the only option.

The consensus says a desirable cut-point for non-fasting triglycerides "has been documented only recently," and chose 175 "according to the recent study from the Women's Health Study," noting that the number is almost identical to cut-points the EAS and an Athens expert panel had suggested before. White and colleagues, writing in Clinical Chemistry in 2015, took non-fasting samples (under 8 hours since the last meal) from 6,391 participants in the Women's Health Study and followed them for up to 17 years. The threshold that best separated women who went on to have cardiovascular events was 175 mg/dL (1.98 mmol/L), with a c-statistic of 0.656 against 0.628 for what the authors call "the AHA cutpoint of 200 mg/dL." Above 175, after adjustment for age, hypertension, smoking, hormone use and menopausal status, the hazard ratio for cardiovascular events was 1.88 (95 percent CI 1.52 to 2.33).

Read that for what it is. It is one cohort of middle-aged and older women the authors describe as apparently healthy, not men and not people with known heart disease, and a c-statistic of 0.656 is a modest ability to sort people by risk. It is the study the consensus based its number on, and if you have seen 200 quoted as the non-fasting limit, that is the older AHA cutpoint this study compared against and outperformed.

The fasting line was then set from the non-fasting one. The consensus took 150 mg/dL as 0.3 mmol/L lower than the non-fasting cut-point, "corresponding to the mean maximal increase of triglycerides following habitual food intake," and notes that 150 is the same fasting cut-point the AHA and the EAS had already proposed.

The case for not fasting rests on how little an ordinary meal changes the result. The consensus pooled the large population studies that compared random non-fasting samples with fasting ones and reported the largest average change at 1 to 6 hours after a habitual meal.

An updated analysis of 92,285 Danish adults for the consensus itself gave the same answer: a maximal mean change of 26 mg/dL for triglycerides, while HDL cholesterol, apolipoprotein B and lipoprotein(a) were unchanged.

Those are averages, and the consensus is explicit about the limits. Changes in an individual "will differ from the mean changes," and while most people respond modestly, "rarely some exhibit exaggerated responses." A high-fat meal is the example the consensus gives: the authors treat a fast-food meal such as "a burger, a shake, and fries" as close to a fat tolerance test, and suggest that where fast-food consumption is especially high, patients may be advised to avoid high-fat, fast-food meals on the day of a lipid test. They also note that in people with diabetes, fasting may mask high triglycerides.

The 2026 ACC/AHA multisociety guideline on dyslipidemia, published online on March 13, 2026, "retires and replaces" the 2018 cholesterol guideline. The 2018 guideline had listed "persistent elevations of triglycerides ≥175 mg/dL" among its risk-enhancing factors. The 2026 list splits the line by sample: "TG persistently ≥175 mg/dL (2 mmol/L) (if nonfasting) and ≥150 mg/dL (1.7 mmol/L) (if fasting)." We could not open the guideline's full text on the day we wrote this; that wording is the guideline's risk-enhancer list, its Table 13, as the ACC reproduces it in its Lipid Manager tool.

A risk enhancer is not a diagnosis. The ACC's reproduction heads the list "Risk-Enhancing Factors for Clinician-Patient Risk Discussion": they are inputs to a conversation about whether lipid-lowering treatment makes sense. The same page adds that for most risk enhancers it "remains to be demonstrated" that they add to the risk calculated by the PREVENT-ASCVD equations. The word persistently matters as well: the ACC's reproduction of the guideline's Figure 14 defines persistent hypertriglyceridemia as a fasting triglyceride of 150 or higher after secondary causes are evaluated and managed, after at least 4 to 12 weeks of lifestyle change, and on a stable, maximally tolerated statin dose if one is indicated. On our reading, one non-fasting 190 does not meet that definition.

The consensus keeps fasting for specific situations. Its Table 4 says a fasting sample can sometimes be required when:

• a non-fasting triglyceride is above 440 mg/dL;
• known high triglycerides are being followed in a lipid clinic;
• someone is recovering from pancreatitis caused by high triglycerides;
• someone is starting a medication that causes severe hypertriglyceridemia;
• another test ordered at the same visit needs a fasting or morning sample, such as fasting glucose.

The US line for a repeat sits lower. Summarizing the 2018 guideline, the ACC's Lipid Manager says that for non-fasting triglycerides above 400 mg/dL a repeat fasting lipid profile is recommended; our high triglycerides page covers the 2026 guideline's own fasting-repeat rules. Denmark, which made non-fasting testing its standard in 2009, gives clinicians the option of a fasting re-measurement above 350 mg/dL, according to the consensus.

Check how your sample was taken before you compare it with anything. Our triglycerides reference page and its band pages, normal, borderline high, high and very high, use fasting categories. A non-fasting 160 falls in the fasting borderline-high band but under the non-fasting line of 175, which is why our borderline-high page reads a non-fasting 150 to 174 separately. The lab result lookup shows where a value sits against those sourced ranges.

Triglycerides are one line of a panel. Our guide to cholesterol levels by age covers the current LDL goals and the other numbers on the same report, and apoB versus LDL cholesterol explains a marker the consensus found unaffected by a meal. To see which tests are due for you, build your personal screening plan.

Bring a non-fasting triglyceride of 175 or more to your next review and ask whether a repeat, fasting or not, is the right next step. Ask sooner if a result is above 400, if you have had pancreatitis, or if you are starting a medicine your prescriber has said can raise triglycerides. Above 880 mg/dL, the consensus calls the level life-threatening because of the risk of pancreatitis and says such a result should trigger an immediate referral to a lipid clinic or a physician with a special interest in lipids.